231 related articles for article (PubMed ID: 17143537)
1. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of alpha3 integrin and MMP-2 expression and activity.
Moretti RM; Montagnani Marelli M; Mai S; Limonta P
Int J Oncol; 2008 Aug; 33(2):405-13. PubMed ID: 18636163
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells.
Marelli MM; Moretti RM; Dondi D; Motta M; Limonta P
Endocrinology; 1999 Jan; 140(1):329-34. PubMed ID: 9886842
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling.
Montagnani Marelli M; Moretti RM; Procacci P; Motta M; Limonta P
Int J Oncol; 2006 Mar; 28(3):723-30. PubMed ID: 16465378
[TBL] [Abstract][Full Text] [Related]
6. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
9. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
10. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
[TBL] [Abstract][Full Text] [Related]
11. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
Iacopino F; Lama G; Angelucci C; Sica G
Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
[TBL] [Abstract][Full Text] [Related]
12. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells.
Sica G; Iacopino F; Settesoldi D; Zelano G
Eur Urol; 1999; 35 Suppl 1():2-8. PubMed ID: 10081696
[TBL] [Abstract][Full Text] [Related]
13. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
14. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
Kooijman R; Himpe E; Potikanond S; Coppens A
Growth Horm IGF Res; 2007 Oct; 17(5):383-91. PubMed ID: 17513150
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer.
Kawada M; Inoue H; Masuda T; Ikeda D
Cancer Res; 2006 Apr; 66(8):4419-25. PubMed ID: 16618768
[TBL] [Abstract][Full Text] [Related]
16. Direct effect of a gonadotropin-releasing hormone agonist on the growth of canine mammary tumour cells.
Pagnini U; Florio S; Crispino L; Pagnini G; Colangelo D; Rocco D; Pacilio C; Pacilio M; Macaluso M; Giordano A
J Cell Biochem; 2002; 85(3):470-81. PubMed ID: 11967986
[TBL] [Abstract][Full Text] [Related]
17. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.
Ko YH; Ha YR; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Cheon J
J Int Med Res; 2011; 39(3):729-39. PubMed ID: 21819703
[TBL] [Abstract][Full Text] [Related]
18. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
19. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system.
Dondi D; Festuccia C; Piccolella M; Bologna M; Motta M
Oncol Rep; 2006 Feb; 15(2):393-400. PubMed ID: 16391860
[TBL] [Abstract][Full Text] [Related]
20. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
